Jefferies reiterates Buy on BridgeBio Pharma stock, $100 target By Investing.com

Jefferies reiterated a Buy rating on BridgeBio Pharma with a $100 price target versus a current share price of $77.70, citing Attruby sales in ATTR-CM that could exceed the $173 million consensus when Q1 results are reported on April 30. The firm also highlighted more than $9 billion of valuation support from BridgeBio’s pipeline, including BBP-418, Encaleret, and Infigratinib, while noting legal risk from the upcoming Pfizer tafamidis/generics court case. Overall, the article is constructive on BridgeBio’s outlook, with analysts pointing to strong revenue growth, high gross margins, and potential long-term profitability.

Analysis

The setup is increasingly a “show-me” quarter rather than a discovery story. BBIO’s rerating is being driven by the market’s willingness to underwrite a multi-asset oral franchise, but the real lever is not just first-quarter sales — it is whether management can prove durable repeat prescribing and payer friction that looks manageable in a category with a credible generic overhang elsewhere. If Attruby prints above consensus again, the stock can continue to de-rate the perceived binary around the core asset and shift valuation toward a sum-of-the-parts model where pipeline optionality matters more than near-term earnings.

The most important second-order effect is competitive timing. A delayed legal outcome on the incumbent therapy creates a longer window for BBIO to entrench before pricing pressure arrives, which means every quarter of strong uptake increases the eventual switching cost for physicians and specialty pharmacies. That also raises the bar for PFE: even if the legal process eventually protects the incumbent, the economic damage may already be done if prescribers migrate to the newer option and do not come back.

The contrarian risk is that the market is extrapolating too cleanly from one high-growth quarter into a straight-line adoption curve. BBIO’s valuation is now sensitive to any signal of payer pushback, slower refill rates, or an earlier-than-expected competitive settlement that compresses the exclusivity runway; those would matter more than a small earnings miss because the stock is trading on NPV, not current EPS. On the other hand, the stock is still not priced like a fully de-risked platform, so a clean quarter plus continued pipeline execution could force another leg higher even without fundamental perfection.

For PFE, the risk is asymmetric but indirect: this is less about immediate revenue leakage and more about losing the ability to defend category economics in a way that supports future launches. If the court process stalls or weakens, the read-through is that specialty oral drugs with better convenience can win before litigation finishes, which is a negative for legacy chronic-disease franchises more broadly. That makes the event worth watching not only as a BBIO catalyst, but as a template for how quickly branded share can erode once a better-tolerated therapy has real distribution.

Key Decisions for Investors

• Stay long BBIO into the 4/30 print, but hedge event risk with a May/June put spread financed against upside: the risk/reward is attractive if sales beat and guidance is reaffirmed, while downside is capped if payer commentary turns cautious.
• Add on pullbacks only, not into strength, because the stock is already pricing multiple quarters of execution; use any post-earnings dip >8% as a tactical entry if Attruby beats consensus and management holds pipeline timelines.
• For relative value, consider a long BBIO / short PFE pair into the late-April legal window: BBIO benefits from incremental de-risking while PFE faces an asymmetry where a negative legal read-through can pressure broader therapeutic credibility.
• If BBIO trades above the prior 52-week high after earnings, take partial profits on 25-33% of the position and let the remainder ride with a trailing stop, because the next upside leg likely depends on pipeline catalysts rather than the quarter itself.
• Avoid chasing momentum in PFE until the court case direction is clearer; if the legal process signals a delayed resolution without settlement, use that as a setup to fade the legacy incumbent rather than buy the dip.